The AGGF1 Knockout PaTu 8988t Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population in which the AGGF1 gene is disrupted. This model, derived from the PaTu 8988t pancreatic adenocarcinoma line, is provided as a heterogeneous knockout pool to avoid clonal artifacts. The loss-of-function approach eliminates AGGF1 expression, enabling dissection of its angiogenic functions in a genetically defined cancer model.
The parental PaTu 8988t cell line is a metastatic pancreatic ductal adenocarcinoma model containing KRAS G12V and TP53 mutations. These well-characterized mutations drive aggressive tumor behavior and are highly relevant for translational studies. The cells retain invasive properties and are commonly employed to investigate tumor progression, metastasis, and the tumor microenvironment. Using this polyclonal knockout background preserves the genetic heterogeneity of the parental line while specifically ablating AGGF1.
AGGF1 is a secreted angiogenic factor that functions through binding to endothelial cell surface receptors, including VEGFR2 and integrin ??v??3. Upstream regulators such as VEGFA, TNF-alpha, and shear stress modulate its expression. Downstream, AGGF1 activates AKT1, MAPK3/1 (ERK1/2), and NOS3 via the PI3K-AKT and ERK signaling cascades, with PIK3CA acting as a critical intermediary. This signaling network promotes endothelial cell proliferation, migration, and tube formation, establishing AGGF1 as a key node in angiogenic regulation.
In the PaTu 8988t context, loss of AGGF1 disrupts tumor-derived pro-angiogenic signals. Given the KRAS/TP53-mutant background, this knockout model allows investigation of how oncogenic pathways intersect with AGGF1-mediated angiogenesis. The absence of AGGF1 is expected to impair endothelial cell stimulation, thus serving as a platform for studying tumor vascular biology, angiocrine factor contributions, and pancreatic cancer progression.
Applications include validation of knockout by western blotting or RT-qPCR, endothelial cell proliferation and tube formation assays, phospho-AKT/ERK analysis, migration assays, immunofluorescence, and in vivo Matrigel plug angiogenesis assays. This product supports anti-angiogenic drug screening, metastasis research, and pancreatic cancer vascular studies. Contact Ascent Research for further information.
